Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Recruiting · NCT06887907 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Toulouse
View the official record on ClinicalTrials.gov →What this trial is about
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Sickle cell disease SS or S-béta° thalassemia
- Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
- Age \> 18 years old
Exclusion criteria
- Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)
- Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
- Anti-platelets agents
- Red blood cell exchange or transfusion \< 3 months
Where it is running
1 location listed.
- CHU de Toulouse - Toulouse, France, France